Novartis announced plans to build a flagship manufacturing hub in North Carolina as part of a broader $23 billion U.S. investment. The program will add biologics and sterile‑packaging facilities in Durham, a solid‑dosage site in Morrisville, and expand existing sterile filling capacity. The company expects phased openings starting in 2027–2028 and said the hub will support end‑to‑end production of key medicines for U.S. patients. CEO Vas Narasimhan said the investment is meant to secure supply chains and scale production of advanced therapies including cell, gene and radioligand medicines while creating hundreds of direct and thousands of indirect jobs.